For the quarter ended March 2023, Jazz Pharmaceuticals (JAZZ) reported revenue of $892.81 million, up 9.7% over the same period last year. EPS came in at $3.95, compared to $3.73 in the year-ago quarter.
The reported revenue represents a surprise of -0.59% over the Zacks Consensus Estimate of $898.11 million. With the consensus EPS estimate being $4.26, the EPS surprise was -7.28%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $884.22 million versus $890.37 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
- Revenues- Royalties and contract revenues: $8.59 million versus the nine-analyst average estimate of $7.74 million. The reported number represents a year-over-year change of +121.2%.
- Total revenues- Oncology- Defitelio(defibrotide)/defibrotide: $39.08 million versus the eight-analyst average estimate of $50.38 million. The reported number represents a year-over-year change of -21%.
- Total revenues- Oncology- Vyxeos: $36.70 million versus the eight-analyst average estimate of $33.84 million. The reported number represents a year-over-year change of +8.7%.
- Total revenues- Oncology- Zepzelca (lurbinectedin): $67.18 million compared to the $74.48 million average estimate based on eight analysts. The reported number represents a change of +13.2% year over year.
- Total revenues- Other: $3.43 million compared to the $1.06 million average estimate based on eight analysts. The reported number represents a change of +264.2% year over year.
- Total revenues- Neuroscience- Epidiolex/Epidyolex: $188.91 million versus $193.03 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +19.6% change.
- Total revenues- Oxybate- Xyrem: $178.13 million compared to the $185.19 million average estimate based on seven analysts. The reported number represents a change of -28% year over year.
- Total revenues- Neuroscience- Sativex: $7.10 million versus the seven-analyst average estimate of $4.36 million. The reported number represents a year-over-year change of +49.7%.
- Total revenues- Oncology- Rylaze: $85.93 million compared to the $74.14 million average estimate based on seven analysts.
- Total revenues- Oxybate- Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: $277.76 million versus the seven-analyst average estimate of $269.85 million. The reported number represents a year-over-year change of +49.3%.
- Total revenues- Total Oxybate: $455.89 million compared to the $453.72 million average estimate based on six analysts. The reported number represents a change of +5.2% year over year.
Shares of Jazz have returned -7.7% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
